AR087484A2 - Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica - Google Patents
Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceuticaInfo
- Publication number
- AR087484A2 AR087484A2 ARP120102894A ARP120102894A AR087484A2 AR 087484 A2 AR087484 A2 AR 087484A2 AR P120102894 A ARP120102894 A AR P120102894A AR P120102894 A ARP120102894 A AR P120102894A AR 087484 A2 AR087484 A2 AR 087484A2
- Authority
- AR
- Argentina
- Prior art keywords
- dihydrotestosterone
- testosterone
- pharmaceutical composition
- group
- value
- Prior art date
Links
- 239000003098 androgen Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 abstract 7
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 4
- 150000003515 testosterones Chemical class 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 229960003473 androstanolone Drugs 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 229960003604 testosterone Drugs 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000039 congener Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Una composición farmacéutica que comprende: (A) de 0,01% a 15% en peso de un andrógeno seleccionado del grupo constituido por testosterona, precursores de testosterona, sales de testosterona, complejos de testosterona, análogos de testosterona, derivados de testosterona, dihidrotestosterona, precursores de dihidrotestosterona, congéneres de dihidrotestosterona, sales de dihidrotestosterona, complejos de dihidrotestosterona, análogos de dihidrotestosterona y derivados de dihidrotestosterona; (B) de 0,01% a 25% en peso de un potenciador de Hsieh, que es un compuesto de la fórmula estructural (1) en la que X e Y son oxígeno, azufre o un grupo imino de la estructura de fórmula (2) o =N-R; con la condición de que cuando Y es un grupo imino, X es un grupo imino, y cuando Y es azufre, X es azufre o un grupo imino; A es un grupo que tiene la estructura de fórmula (3) en la que X e Y son como se han definido anteriormente; m y n son números enteros que tienen un valor de 1 a 20 y la suma de m + n no es mayor de 25; p es un número entero que tiene un valor de 0 ó 1; q es un número entero que tiene un valor de 0 ó 1; r es un número entero que tiene un valor de 0 ó 1; y cada uno de R, R1, R2, R3, R4, R5 y R6 es de manera independiente hidrógeno o un grupo alquilo que tiene de 1 a 6 átomos de carbono que puede ser de cadena lineal o ramificada, con la condición de que sólo uno de R1 a R6 puede ser un grupo alquilo; con la condición de que cuando p, q y r son 0, e Y es oxígeno, entonces m + n es al menos 11; y con la condición adicional de que cuando X es un grupo imino, q es igual a 1, Y es oxígeno, y p y r son 0, entonces m + n es al menos 11; (C) de 0,1% a 10% en peso de un agente espesante; y el uso de la composición para la fabricación de un medicamento para administrar un andrógeno a un paciente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37410302P | 2002-04-19 | 2002-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087484A2 true AR087484A2 (es) | 2014-03-26 |
Family
ID=29251138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101362A AR039644A1 (es) | 2002-04-19 | 2003-04-21 | Composicion farmaceutica que comprende un androgeno, un mejorador de hsieh y un agente espesante. |
| ARP120102894A AR087484A2 (es) | 2002-04-19 | 2012-08-08 | Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101362A AR039644A1 (es) | 2002-04-19 | 2003-04-21 | Composicion farmaceutica que comprende un androgeno, un mejorador de hsieh y un agente espesante. |
Country Status (29)
| Country | Link |
|---|---|
| US (21) | US7320968B2 (es) |
| EP (2) | EP1741433B1 (es) |
| JP (1) | JP2005519985A (es) |
| KR (2) | KR100952786B1 (es) |
| CN (2) | CN102357098B (es) |
| AR (2) | AR039644A1 (es) |
| AT (1) | ATE371456T1 (es) |
| AU (1) | AU2003228612B2 (es) |
| BR (1) | BR0309390A (es) |
| CA (1) | CA2470200C (es) |
| CY (1) | CY1109005T1 (es) |
| DE (1) | DE60315939T2 (es) |
| DK (1) | DK1425019T3 (es) |
| EA (1) | EA009839B1 (es) |
| EG (1) | EG24882A (es) |
| ES (2) | ES2292964T3 (es) |
| IL (1) | IL164547A (es) |
| IS (2) | IS2667B (es) |
| LT (1) | LT5235B (es) |
| LV (1) | LV13303B (es) |
| MX (1) | MXPA04010311A (es) |
| MY (1) | MY139721A (es) |
| NO (1) | NO335864B1 (es) |
| NZ (1) | NZ535970A (es) |
| PL (1) | PL213976B1 (es) |
| SA (1) | SA03240158B1 (es) |
| TW (1) | TWI362932B (es) |
| WO (1) | WO2003088974A1 (es) |
| ZA (1) | ZA200408422B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| US20040072810A1 (en) * | 2001-11-07 | 2004-04-15 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| ATE474591T1 (de) | 2003-12-08 | 2010-08-15 | Cpex Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung |
| BRPI0515040B1 (pt) * | 2004-09-09 | 2021-10-13 | Besins Healthcare Luxembourg S.A.R.L | Géis de testosterona compreendendo propileno glicol como intensificador de penetração |
| EP1634583A1 (en) | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| FI3456329T3 (fi) | 2005-10-12 | 2025-02-27 | Besins Healthcare Lu Sarl | Parannettu testosteronigeeli ja käyttömenetelmä |
| US20090280069A1 (en) * | 2008-05-09 | 2009-11-12 | Tolmar, Inc. | Proguanil to treat skin/mucosal diseases |
| WO2009149368A1 (en) * | 2008-06-05 | 2009-12-10 | Cpex Pharmaceuticals, Inc. | Nasal formulations of insulin |
| WO2011049776A1 (en) * | 2009-10-22 | 2011-04-28 | Cpex Pharmaceuticals, Inc. | Therapeutically effective preparations of insulin |
| JP6912852B2 (ja) | 2010-11-18 | 2021-08-04 | ホワイト マウンテン ファーマ，インコーポレイテッド | 対象における慢性または解決不能な疼痛を処置するための、および／または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物 |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| MX2013013369A (es) * | 2011-05-15 | 2014-10-17 | Trimel Biopharma Srl | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino. |
| US10568905B2 (en) * | 2012-02-14 | 2020-02-25 | Metabolic Therapy Inc. | Pharmaceutical composition and method for treating retinal neurodegeneration |
| EP4186545A1 (en) | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| IN2015KN00677A (es) | 2012-09-20 | 2015-07-17 | Gkn Armstrong Wheels Inc | |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| US8785426B1 (en) | 2013-12-13 | 2014-07-22 | Upsher-Smith Laboratories, Inc. | Testosterone gel compositions and related methods |
| US20170014417A1 (en) | 2015-07-14 | 2017-01-19 | Lipp Life Sciences Llc | Pharmaceutical administration system for the transdermal application of vardenafil |
| WO2019089942A1 (en) * | 2017-11-02 | 2019-05-09 | Rick Coulon | Formulations for use in the transdermal delivery of proteasome inhibitors |
| CN112666197B (zh) * | 2020-11-29 | 2022-11-04 | 山东大学 | 一种用于tbm的岩渣石英含量测试系统及方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US3989815A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Novel N-bis-azacyclopentan-2-onyl alkanes |
| BE843140A (fr) * | 1975-06-19 | 1976-10-18 | Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients | |
| US3991203A (en) * | 1975-06-19 | 1976-11-09 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US4444762A (en) * | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US4415563A (en) * | 1980-04-04 | 1983-11-15 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclononan-2-ones |
| US4424210A (en) * | 1980-04-04 | 1984-01-03 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4423040A (en) * | 1980-04-04 | 1983-12-27 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclohexan-2-ones |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5731303A (en) | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
| US5270346A (en) | 1986-01-31 | 1993-12-14 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
| US4992422A (en) * | 1986-01-31 | 1991-02-12 | Whitby Research, Inc. | Compositions comprising 1-substituted azacycloalkanes |
| US4801586A (en) | 1986-04-23 | 1989-01-31 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agents |
| US4879275A (en) | 1987-09-30 | 1989-11-07 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agent |
| US5019395A (en) | 1988-03-08 | 1991-05-28 | Warner-Lambert Company | Compositions with enhanced penetration |
| US5676968A (en) * | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
| US6190691B1 (en) * | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| DE19619045C1 (de) | 1996-05-02 | 1997-11-13 | Jenapharm Gmbh | Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6019997A (en) * | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
| DE19701949A1 (de) | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
| NZ336900A (en) * | 1997-01-30 | 2001-06-29 | Novartis Ag | Hard gelatine capsules containing pharmaceutical compositions comprising cyclosporin A and being substantially free of any oil |
| DE19709960A1 (de) * | 1997-03-11 | 1998-09-24 | Aesculap Ag & Co Kg | Verfahren und Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen |
| US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
| ES2318233T3 (es) | 1997-11-10 | 2009-05-01 | Strakan International Limited | Sistemas mejoradores de la penetracion y reductores de la irritacion que comprenden testosterona. |
| US6980952B1 (en) * | 1998-08-15 | 2005-12-27 | Texas Instruments Incorporated | Source normalization training for HMM modeling of speech |
| EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| FR2801507B1 (fr) * | 1999-11-30 | 2003-06-27 | Pf Medicament | Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations |
| ES2299441T3 (es) * | 1999-12-08 | 2008-06-01 | Pharmacia Corporation | Forma en estado solido de celecoxib con biodisponibilidad potenciada. |
| US6495124B1 (en) | 2000-02-14 | 2002-12-17 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| DE60143360D1 (de) * | 2000-08-03 | 2010-12-09 | Antares Pharma Ipl Ag | Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| CN1473047A (zh) | 2000-08-30 | 2004-02-04 | ������ҩ������˾ | 治疗男性勃起功能障碍和增强性冲动的方法 |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| CN100349572C (zh) * | 2000-08-30 | 2007-11-21 | 尤尼麦德制药公司 | 提高妇女睾酮和相关类固醇浓度的方法 |
| US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20040002482A1 (en) | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US6743448B2 (en) | 2000-12-11 | 2004-06-01 | Abraham H. Kryger | Topical testosterone formulations and associated methods |
| ES2283446T3 (es) | 2000-12-22 | 2007-11-01 | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL | Composicion de gel basada en alcohol para el tratamiento del hipogonadismo por administracion transescrotal. |
| CA2446060A1 (en) * | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US7169107B2 (en) | 2002-01-25 | 2007-01-30 | Karen Jersey-Willuhn | Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system |
| HU230920B1 (hu) | 2002-03-15 | 2019-03-28 | Besins Healthcare Luxembourg Sarl | Depresszió kezelésére szolgáló androgén gyógyászati készítmények |
| MY139721A (en) | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| US20040259784A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Compositions and methods for treatment of muscle pain and muscle wasting |
-
2003
- 2003-04-18 MY MYPI20031462A patent/MY139721A/en unknown
- 2003-04-19 EG EG2003040351A patent/EG24882A/xx active
- 2003-04-21 AU AU2003228612A patent/AU2003228612B2/en not_active Ceased
- 2003-04-21 ES ES03726373T patent/ES2292964T3/es not_active Expired - Lifetime
- 2003-04-21 EP EP06018822A patent/EP1741433B1/en not_active Expired - Lifetime
- 2003-04-21 AR ARP030101362A patent/AR039644A1/es not_active Application Discontinuation
- 2003-04-21 KR KR1020047016828A patent/KR100952786B1/ko not_active Expired - Fee Related
- 2003-04-21 NZ NZ535970A patent/NZ535970A/en not_active IP Right Cessation
- 2003-04-21 AT AT03726373T patent/ATE371456T1/de active
- 2003-04-21 CA CA002470200A patent/CA2470200C/en not_active Expired - Fee Related
- 2003-04-21 US US10/473,724 patent/US7320968B2/en not_active Expired - Lifetime
- 2003-04-21 DE DE60315939T patent/DE60315939T2/de not_active Expired - Lifetime
- 2003-04-21 DK DK03726373T patent/DK1425019T3/da active
- 2003-04-21 EA EA200401410A patent/EA009839B1/ru not_active IP Right Cessation
- 2003-04-21 BR BR0309390-5A patent/BR0309390A/pt not_active IP Right Cessation
- 2003-04-21 ES ES06018822T patent/ES2399900T3/es not_active Expired - Lifetime
- 2003-04-21 MX MXPA04010311A patent/MXPA04010311A/es active IP Right Grant
- 2003-04-21 CN CN201110259341.7A patent/CN102357098B/zh not_active Expired - Fee Related
- 2003-04-21 WO PCT/US2003/012235 patent/WO2003088974A1/en not_active Ceased
- 2003-04-21 TW TW092109215A patent/TWI362932B/zh not_active IP Right Cessation
- 2003-04-21 EP EP03726373A patent/EP1425019B1/en not_active Expired - Lifetime
- 2003-04-21 PL PL372083A patent/PL213976B1/pl unknown
- 2003-04-21 JP JP2003585726A patent/JP2005519985A/ja active Pending
- 2003-04-21 KR KR1020097013431A patent/KR100977896B1/ko not_active Expired - Fee Related
- 2003-04-21 CN CN038142368A patent/CN1662243B/zh not_active Expired - Fee Related
- 2003-06-22 SA SA03240158A patent/SA03240158B1/ar unknown
-
2004
- 2004-10-13 IL IL164547A patent/IL164547A/en not_active IP Right Cessation
- 2004-10-18 ZA ZA200408422A patent/ZA200408422B/en unknown
- 2004-10-27 LV LVP-04-127A patent/LV13303B/en unknown
- 2004-11-17 IS IS7535A patent/IS2667B/is unknown
- 2004-11-18 LT LT2004101A patent/LT5235B/lt not_active IP Right Cessation
- 2004-11-18 NO NO20045019A patent/NO335864B1/no not_active IP Right Cessation
-
2007
- 2007-10-30 US US11/929,610 patent/US20080103120A1/en not_active Abandoned
- 2007-10-30 US US11/928,467 patent/US7935690B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/930,812 patent/US8063029B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,809 patent/US8178518B2/en not_active Expired - Fee Related
- 2007-11-26 CY CY20071101504T patent/CY1109005T1/el unknown
-
2009
- 2009-01-20 US US12/356,515 patent/US7608606B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/356,513 patent/US7608605B2/en not_active Expired - Fee Related
- 2009-01-21 US US12/356,943 patent/US7608607B2/en not_active Expired - Fee Related
- 2009-01-23 US US12/359,162 patent/US7608608B2/en not_active Expired - Fee Related
- 2009-01-23 US US12/359,183 patent/US7608609B2/en not_active Expired - Fee Related
- 2009-02-02 US US12/364,413 patent/US7608610B2/en not_active Expired - Fee Related
- 2009-03-19 US US12/407,418 patent/US20090192131A1/en not_active Abandoned
- 2009-03-19 US US12/407,460 patent/US20090192132A1/en not_active Abandoned
- 2009-09-30 US US12/570,847 patent/US20100081640A1/en not_active Abandoned
-
2010
- 2010-01-06 IS IS8870A patent/IS2946B/is unknown
-
2012
- 2012-04-11 US US13/444,637 patent/US20210308145A1/en not_active Abandoned
- 2012-08-03 US US13/566,633 patent/US20210308146A1/en not_active Abandoned
- 2012-08-08 AR ARP120102894A patent/AR087484A2/es unknown
- 2012-08-31 US US13/601,572 patent/US20130059828A1/en not_active Abandoned
-
2013
- 2013-06-19 US US13/921,879 patent/US20130281416A1/en not_active Abandoned
-
2014
- 2014-03-04 US US14/196,705 patent/US20140343025A1/en not_active Abandoned
-
2015
- 2015-04-07 US US14/680,197 patent/US20150283153A1/en not_active Abandoned
-
2016
- 2016-01-19 US US15/000,848 patent/US20160129016A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087484A2 (es) | Una composicion farmaceutica que comprende un androgeno, un potenciador de hsieh y un agente espesante, y el uso de la composicion farmaceutica | |
| HUP0302468A2 (hu) | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
| AR024634A1 (es) | Composicion farmaceutica estabilizada en forma liofilizada | |
| PL1802650T3 (pl) | 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C | |
| DK1157037T3 (da) | GCSF-konjugater | |
| AR035885A1 (es) | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
| PE20080093A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| AR098830A2 (es) | Suspensiones acuosas estabilizadas para administración parenteral | |
| AR036248A1 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| MX9202328A (es) | Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo. | |
| AR045234A1 (es) | Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen. | |
| TW200609235A (en) | Tetraazabenzo[e]azulene derivatives and analogs thereof | |
| ECSP088239A (es) | Composición de liberación de fármaco sostenida | |
| ATE391708T1 (de) | Verbindungen und gemische zur verabreichung eines aktiven agens | |
| HUP0402458A2 (hu) | Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek | |
| AR071959A1 (es) | Derivado de benceno o tiofeno y su uso como inhibidor de vap-1 | |
| BRPI0519345A2 (pt) | composiÇço para tratamento do hcv | |
| PE20030727A1 (es) | 17OALQUIL-17ß-OXI-ESTRATRIENOS, PRODUCTOS INTERMEDIARIOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| PE20040949A1 (es) | DERIVADOS DE HEXAHIDRO-PIRAZINO [1,2-a] PIRIMIDIN-4,7-DIONA SUSTITUIDOS EN POSICION 3 POR NITROGENO Y PROCEDIMIENTO PARA LA PREPARACION DE LA COMPOSICION FARMACEUTICA | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| ECSP088240A (es) | Composición de trazodona para administración una vez por día | |
| SA522431498B1 (ar) | مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا | |
| CO6180500A2 (es) | Composiciones de fenilalquilamino-carbamato |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |